The Global Reach of Malaria at the Dawn of the 20th Century

Malaria has shadowed human existence for thousands of years, but the 20th century represented a watershed era in the battle against this ancient scourge. When the century opened, malaria was entrenched across broad swaths of the planet, from the marshlands of the American South to the river deltas of Southeast Asia and the high plateaus of East Africa. The disease exacted a catastrophic toll: hundreds of millions of people suffered acute fevers each year, millions perished, and entire regions were locked in cycles of poverty partly because of the constant burden of illness. Life expectancy in heavily endemic areas was sharply reduced, and some fertile lands remained sparsely populated due to the risk of infection. To grasp how the struggle against malaria evolved over these hundred years, one must examine the interplay of scientific discovery, military necessity, colonial politics, international cooperation, and the rise of resistance to drugs and insecticides.

Foundations of Modern Malaria Control: 1900–1939

The Parasite and the Mosquito Revealed

The intellectual breakthrough that made modern malaria control possible occurred just before the turn of the century. In 1897, British army doctor Ronald Ross demonstrated that Plasmodium parasites developed within Anopheles mosquitoes and were transmitted through their bites. Italian scientists Giovanni Battista Grassi, Amico Bignami, and Giuseppe Bastianelli soon confirmed the full transmission cycle in humans. This discovery transformed malaria from a mysterious miasma attributed to bad air into a biologically understood infectious disease with a clear weak point: the mosquito vector. Public health officials now had a rational target for intervention.

Quinine: The Drug That Shaped an Era

For centuries, quinine extracted from cinchona bark had been the only reliable treatment for malarial fevers. At the start of the 20th century, quinine remained central to both treatment and prophylaxis, but its supply was precarious. The Dutch controlled the vast majority of cinchona plantations on Java, creating a near-monopoly that could be disrupted by war or political upheaval. During World War I, shortages of quinine hampered military campaigns in Macedonia, East Africa, and Mesopotamia, forcing Allied forces to ration supplies and search for alternatives. The side effects of quinine — tinnitus, nausea, headache, and visual disturbances, collectively known as cinchonism — discouraged adherence among both troops and civilian populations. Despite these drawbacks, quinine remained the frontline antimalarial through the 1930s, and the search for synthetic substitutes accelerated in the interwar years.

Early Vector Control: Drainage, Oiling, and Screening

Armed with knowledge of the mosquito's role, early 20th century public health campaigns focused on environmental management. The logic was straightforward: eliminate mosquito breeding sites, and transmission would collapse. Drainage of swamps and marshes, filling of depressions, clearing of brush, and straightening of streams were carried out in colonial territories, southern US states, and parts of Latin America. The most celebrated success was in the Panama Canal Zone, where Colonel William Gorgas directed a comprehensive program of drainage, oiling of standing water, screening of buildings, and quinine distribution. Malaria incidence among canal workers plummeted, enabling the completion of the canal. However, such intensive environmental measures were expensive, labor-intensive, and difficult to sustain across large rural areas. Larviciding with Paris green, an arsenic-based compound, was used in some settings but required repeated application and posed risks to applicators. Bed nets, window screens, and mosquito repellents offered partial protection but were not widely adopted in poor rural communities. By the late 1930s, malaria remained a massive global problem despite decades of control efforts.

The Insecticide Revolution: DDT and the Promise of Eradication

DDT Emerges as a Miracle Chemical

The discovery of DDT's insecticidal properties by Swiss chemist Paul Müller in 1939 was a turning point. DDT was cheap, stable, highly toxic to insects, and had low acute toxicity to mammals. During World War II, it was used to delouse troops and protect against typhus, and then to control malaria mosquitoes in the Pacific and Mediterranean theaters. After the war, DDT became the cornerstone of global malaria control. Indoor residual spraying (IRS) with DDT proved remarkably effective: a single application could kill mosquitoes for months. In Sri Lanka (then Ceylon), malaria cases fell from 2.8 million in 1946 to just 17 in 1963. In India, cases dropped from an estimated 75 million to fewer than 100,000 by the early 1960s. Similar successes were recorded in parts of Africa, Latin America, and southern Europe. Emboldened by these results, the World Health Organization launched the Global Malaria Eradication Program (GMEP) in 1955, aiming to eliminate the disease worldwide through universal DDT spraying and case detection.

The Retreat from DDT: Resistance and Environmental Backlash

By the mid-1960s, the eradication campaign began to unravel. Mosquito populations in many regions evolved resistance to DDT, first noted in agricultural areas where the chemical was used intensively. The same resistance genes spread into malaria vectors, reducing the effectiveness of spraying. At the same time, Rachel Carson's Silent Spring (1962) exposed the ecological costs of persistent pesticides: DDT accumulated in the food chain, thinning the eggshells of birds of prey and causing population declines. Public concern led to restrictions and bans on DDT in the United States and many other countries, though its use for public health vector control continued under strict guidelines in some endemic areas. The combination of resistance, rising costs, logistical difficulties in remote areas, and waning political commitment forced the WHO to abandon the global eradication goal in 1969. The aftermath was a period of neglect: malaria resurged dramatically in many countries that had previously brought it under control. Sri Lanka, which had achieved near-elimination, saw cases climb back to over 500,000 by 1969. Sub-Saharan Africa, where transmission was most intense and health systems weakest, had never been brought under control at all.

The Drug Treatment Story: From Chloroquine to Artemisinin

Chloroquine: The Wonder Drug That Failed

Alongside vector control, the mid-20th century saw the development of synthetic antimalarials that revolutionized treatment. Chloroquine, first synthesized in 1934 but not widely deployed until the 1940s, was cheap, safe, well-tolerated, and highly effective against all Plasmodium species. It became the mainstay of malaria treatment and prophylaxis for decades. Mass drug administration campaigns using chloroquine were attempted in isolated populations, but logistical hurdles and poor compliance limited their impact. The drug's ease of use and low cost made it indispensable in primary health care across Africa and Asia. However, the first signs of resistance appeared in the late 1950s along the Thai-Cambodian border and in South America. Chloroquine-resistant P. falciparum spread relentlessly during the 1960s and 1970s, reaching East Africa by the late 1970s and West Africa by the 1980s. By the 1990s, chloroquine was largely ineffective in most endemic regions, and malaria mortality began to rise again after decades of decline.

The Artemisinin Revolution

The loss of chloroquine to resistance created an urgent need for new drugs. The breakthrough came from an unlikely source: traditional Chinese medicine. In the 1970s, Chinese scientist Youyou Tu, reviewing ancient texts on herbal remedies for fever, identified sweet wormwood (Artemisia annua) as a promising candidate. She isolated artemisinin, a compound with potent and rapid antimalarial activity, even against multi-drug-resistant parasites. Artemisinin derivatives, such as artesunate and artemether, proved to be the most powerful antimalarials ever developed. In the 1990s, the concept of artemisinin-based combination therapy (ACT) was developed: pairing a fast-acting artemisinin with a longer-acting partner drug to reduce the risk of resistance. By the early 2000s, the WHO recommended ACTs as the first-line treatment for uncomplicated P. falciparum malaria worldwide. The widespread introduction of ACTs, supported by global funding mechanisms, contributed to a dramatic decline in malaria mortality between 2000 and 2015. Yet resistance to artemisinin has now emerged in the Greater Mekong Subregion and, worryingly, has been detected in parts of Africa. The clock is ticking on this class of drugs.

Global Campaigns: The Long Arc of International Commitment

The Global Malaria Eradication Program (1955–1969)

The GMEP was the first truly global effort to eliminate a human infectious disease. It was built on four pillars: indoor residual spraying with DDT, active case detection through blood smear surveys, treatment of confirmed cases with chloroquine, and a rigorous surveillance system to track cases and identify foci of transmission. The program achieved remarkable success in temperate and subtropical regions. Malaria was eliminated from Europe, North America, the former Soviet Union, and parts of Latin America, North Africa, and Asia. However, the GMEP largely bypassed sub-Saharan Africa, where weak health systems, intense year-round transmission, and logistical challenges made eradication seem unattainable. By 1969, with resistance spreading, funding dwindling, and political will evaporating, the WHO conceded that global eradication was not feasible in the near term. The program was dismantled, and malaria control entered a period of neglect that lasted into the 1990s.

The Roll Back Malaria Era and Unprecedented Funding

The late 1990s saw a resurgence of global political will to tackle malaria. The Roll Back Malaria partnership was launched in 1998 by the WHO, UNICEF, UNDP, and the World Bank, with the ambitious goal of halving malaria mortality by 2010. What changed the landscape was the arrival of massive new funding sources: the Global Fund to Fight AIDS, Tuberculosis and Malaria (established in 2002), the US President's Malaria Initiative (2005), and major investments from the Bill & Melinda Gates Foundation. These resources enabled the large-scale distribution of insecticide-treated bed nets, expansion of indoor residual spraying, deployment of rapid diagnostic tests, and widespread access to ACTs. The results were impressive: between 2000 and 2015, global malaria mortality fell by approximately 60%, with an estimated 6.2 million lives saved. However, progress has plateaued since 2015. Global cases remain stuck at around 240 million per year, and deaths at roughly 600,000, with the vast majority occurring in African children under five years old.

Contemporary Tools and Research Frontiers

Insecticide-Treated Nets: The Bedrock of Prevention

Long-lasting insecticidal nets (LLINs) have become the primary means of malaria prevention in endemic countries. Treated with pyrethroid insecticides, LLINs provide both a physical barrier against biting mosquitoes and a chemical kill effect. Mass distribution campaigns have achieved high coverage in many African countries, contributing to significant reductions in child mortality. However, the emergence and spread of pyrethroid resistance in Anopheles mosquitoes threatens the effectiveness of LLINs. Researchers are developing nets treated with piperonyl butoxide (PBO), which inhibits resistance enzymes and restores pyrethroid efficacy, as well as nets incorporating new classes of insecticides such as chlorfenapyr and broflanilide. Indoor residual spraying remains a complementary tool but has declined in use due to cost, logistical complexity, and resistance concerns.

Rapid Diagnostics and Modern Surveillance

Accurate diagnosis of malaria was historically dependent on microscopy, which requires trained technicians, electricity, and time — resources often scarce in rural health facilities. The development of rapid diagnostic tests (RDTs) in the 1990s was a game-changer. RDTs detect parasite-specific antigens in a drop of blood and deliver results within 15 minutes, enabling prompt treatment and reducing unnecessary use of antimalarials for other febrile illnesses. RDTs have been deployed at massive scale, with hundreds of millions distributed each year. Modern surveillance systems, including mobile phone reporting platforms and geographic information systems, allow health authorities to track cases in near real-time, identify outbreaks, and target interventions with precision. These tools are essential for moving from control toward elimination.

The First Malaria Vaccine: RTS,S and What Comes Next

After decades of research, the first and still only licensed malaria vaccine, RTS,S/AS01 (Mosquirix), was developed by GlaxoSmithKline in partnership with the Walter Reed Army Institute of Research. In large-scale clinical trials, the vaccine reduced clinical malaria episodes by about 39% over four years and severe malaria by about 30% in young children. In 2021, the WHO recommended its use for children in moderate-to-high transmission areas. Pilot implementation programs in Ghana, Kenya, and Malawi have demonstrated feasibility and some impact on hospitalizations and deaths. However, the vaccine's moderate efficacy, the need for four doses, and waning protection over time limit its potential as a standalone tool. Next-generation vaccines are in the pipeline, including whole-sporozoite vaccines, viral-vectored vaccines, and mRNA-based candidates, aiming for higher efficacy and longer-lasting protection. A vaccine with greater than 75% efficacy could be transformative for malaria control and elimination.

Persistent Challenges: Resistance, Climate, Funding, and Fragility

Despite a century of scientific progress, malaria remains a formidable opponent. Drug resistance to artemisinin and partner drugs is spreading in the Greater Mekong Subregion, and worrisome mutations have been detected in Rwanda and Uganda. Insecticide resistance in Anopheles mosquitoes is now widespread across Africa, threatening the effectiveness of both LLINs and IRS. Climate change is expected to expand the geographical range of malaria transmission into higher altitudes in East Africa and South America, and into new latitudes, putting populations with little immunity at risk. Funding plateaus present a major obstacle: global investments for malaria have stabilized at around $3 billion per year, well short of the estimated $6–7 billion needed to meet elimination targets set by the WHO Global Technical Strategy. Political instability, conflict, and weak health systems in many endemic countries continue to disrupt control efforts and leave vulnerable populations without access to prevention and treatment. The COVID-19 pandemic caused significant disruptions to malaria services, resulting in an increase in cases and deaths in 2020, though the impact was less severe than initially feared.

Looking Ahead: The Path Toward Elimination

The 20th century transformed malaria from a mysterious and deadly curse into a scientifically understood and potentially eradicable disease. The tools available today — ACTs, LLINs, RDTs, IRS, and the RTS,S vaccine — are more effective than any previous generation of interventions. Countries are making progress: 23 countries have reported zero indigenous cases for three years or more, and the WHO has certified 40 countries and territories as malaria-free. Yet the historical record is clear: progress is fragile and easily reversed. The resurgence of malaria in Sri Lanka, India, and elsewhere after the collapse of the GMEP is a cautionary tale. Sustained political will, robust and predictable funding, continuous research into new drugs, insecticides, and vaccines, and strengthened health systems are essential to maintain gains and move toward elimination. A world free of malaria is not a fantasy, but it will require a long-term commitment that extends well beyond any single generation. The story of the fight against malaria in the 20th century is a story of extraordinary human ingenuity and resilience. It is also a warning that victory over infectious disease is never final.

For further reading: WHO Malaria Fact Sheet | CDC History of Malaria | Gates Foundation Malaria Program